Literature DB >> 18722359

Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats.

Yoshinori Omori1, Osamu Honmou, Kuniaki Harada, Junpei Suzuki, Kiyohiro Houkin, Jeffery D Kocsis.   

Abstract

The systemic injection of human mesenchymal stem cells (hMSCs) prepared from adult bone marrow has therapeutic benefits after cerebral artery occlusion in rats, and may have multiple therapeutic effects at various sites and times within the lesion as the cells respond to a particular pathological microenvironment. However, the comparative therapeutic benefits of multiple injections of hMSCs at different time points after cerebral artery occlusion in rats remain unclear. In this study, we induced middle cerebral artery occlusion (MCAO) in rats using intra-luminal vascular occlusion, and infused hMSCs intravenously at a single 6 h time point (low and high cell doses) and various multiple time points after MCAO. From MRI analyses lesion volume was reduced in all hMSC cell injection groups as compared to serum alone injections. However, the greatest therapeutic benefit was achieved following a single high cell dose injection at 6 h post-MCAO, rather than multiple lower cell infusions over multiple time points. Three-dimensional analysis of capillary vessels in the lesion indicated that the capillary volume was equally increased in all of the cell-injected groups. Thus, differences in functional outcome in the hMSC transplantation subgroups are not likely the result of differences in angiogenesis, but rather from differences in neuroprotective effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722359      PMCID: PMC2605387          DOI: 10.1016/j.brainres.2008.07.116

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  28 in total

1.  Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat.

Authors:  T Honma; O Honmou; S Iihoshi; K Harada; K Houkin; H Hamada; J D Kocsis
Journal:  Exp Neurol       Date:  2005-06-20       Impact factor: 5.330

2.  Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat.

Authors:  Yoshifumi Horita; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  J Neurosci Res       Date:  2006-11-15       Impact factor: 4.164

Review 3.  Demyelinating diseases and potential repair strategies.

Authors:  C Radtke; M Spies; M Sasaki; P M Vogt; J D Kocsis
Journal:  Int J Dev Neurosci       Date:  2007-03-03       Impact factor: 2.457

4.  Mesenchymal stem cells derived from peripheral blood protects against ischemia.

Authors:  Ryo Ukai; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  J Neurotrauma       Date:  2007-03       Impact factor: 5.269

5.  Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation.

Authors:  T Neumann-Haefelin; A Kastrup; A de Crespigny; M A Yenari; T Ringer; G H Sun; M E Moseley
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

6.  Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation.

Authors:  M Chopp; X H Zhang; Y Li; L Wang; J Chen; D Lu; M Lu; M Rosenblum
Journal:  Neuroreport       Date:  2000-09-11       Impact factor: 1.837

7.  I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat.

Authors:  T Nomura; O Honmou; K Harada; K Houkin; H Hamada; J D Kocsis
Journal:  Neuroscience       Date:  2005-10-17       Impact factor: 3.590

8.  SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model.

Authors:  Ye Wang; Yubin Deng; Guang-Qian Zhou
Journal:  Brain Res       Date:  2007-12-14       Impact factor: 3.252

9.  One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke.

Authors:  Li Hong Shen; Yi Li; Jieli Chen; Yisheng Cui; Chunling Zhang; Alissa Kapke; Mei Lu; Smita Savant-Bhonsale; Michael Chopp
Journal:  Stroke       Date:  2007-05-24       Impact factor: 7.914

10.  Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia.

Authors:  Toshiyuki Onda; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  J Cereb Blood Flow Metab       Date:  2007-07-18       Impact factor: 6.200

View more
  32 in total

1.  Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke.

Authors:  Osamu Honmou; Kiyohiro Houkin; Takuya Matsunaga; Yoshiro Niitsu; Sumio Ishiai; Rie Onodera; Stephen G Waxman; Jeffery D Kocsis
Journal:  Brain       Date:  2011-04-14       Impact factor: 13.501

Review 2.  Update on therapeutic mechanism for bone marrow stromal cells in ischemic stroke.

Authors:  Huan Wan; Fangqin Li; Lei Zhu; Jing Wang; Zizhen Yang; Yujun Pan
Journal:  J Mol Neurosci       Date:  2013-09-19       Impact factor: 3.444

3.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

4.  Mesenchymal stem cells: Molecular characteristics and clinical applications.

Authors:  Farbod Rastegar; Deana Shenaq; Jiayi Huang; Wenli Zhang; Bing-Qiang Zhang; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Qing Luo; Qiong Shi; Eric R Wagner; Enyi Huang; Yanhong Gao; Jian-Li Gao; Stephanie H Kim; Jian-Zhong Zhou; Yang Bi; Yuxi Su; Gaohui Zhu; Jinyong Luo; Xiaoji Luo; Jiaqiang Qin; Russell R Reid; Hue H Luu; Rex C Haydon; Zhong-Liang Deng; Tong-Chuan He
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

5.  Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair.

Authors:  Nobutaka Horie; Marta P Pereira; Kuniyasu Niizuma; Guohua Sun; Hadar Keren-Gill; Angelo Encarnacion; Mehrdad Shamloo; Scott A Hamilton; Kewen Jiang; Stephen Huhn; Theo D Palmer; Tonya M Bliss; Gary K Steinberg
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

6.  The Unusual Properties of Polytetrafluoroethylene Enable Massive-Volume Vitrification of Stem Cells with Low-Concentration Cryoprotectants.

Authors:  Yuan Cao; Gang Zhao; Fazil Panhwar; Xiaozhang Zhang; Zhongrong Chen; Lin Cheng; Chuanbao Zang; Feng Liu; Yuanjin Zhao; Xiaoming He
Journal:  Adv Mater Technol       Date:  2018-10-17

7.  Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection.

Authors:  Yang Qiao; Joy Gumin; Christopher J MacLellan; Feng Gao; Richard Bouchard; Frederick F Lang; R Jason Stafford; Marites P Melancon
Journal:  Nanotechnology       Date:  2018-04-20       Impact factor: 3.874

8.  The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke.

Authors:  Oh Young Bang; Kyung Sil Jin; Mi Na Hwang; Ho Young Kang; Byoung Joon Kim; Sang Jin Lee; Sangmee Kang; Yu Kyeong Hwang; Jong Seong Ahn; Ki Woong Sung
Journal:  Cell Med       Date:  2012-05-15

Review 9.  Bone marrow stromal cells as a therapeutic treatment for ischemic stroke.

Authors:  Zizhen Yang; Lei Zhu; Fangqin Li; Jing Wang; Huan Wan; Yujun Pan
Journal:  Neurosci Bull       Date:  2014-05-10       Impact factor: 5.203

10.  Mesenchymal stem cells transplantation suppresses inflammatory responses in global cerebral ischemia: contribution of TNF-α-induced protein 6.

Authors:  Qing-ming Lin; Shen Zhao; Li-li Zhou; Xiang-shao Fang; Yue Fu; Zi-tong Huang
Journal:  Acta Pharmacol Sin       Date:  2013-03-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.